Surrogate markers in antiangiogenesis clinical trials

Area of Science:

• Oncology
• Pharmacology

Background:

• Novel antiangiogenic agents are being developed as potentially more effective and less toxic alternatives to traditional cytotoxic chemotherapy for solid tumors.
• Early clinical trials reveal the complexity of targeting angiogenesis, indicating that developing effective antiangiogenic therapies is more challenging than initially anticipated.

Purpose of the Study:

• To review the current clinical data on the development of surrogate markers for angiogenesis inhibitors.
• To highlight the necessity of new methods and markers for evaluating the biological activity of antiangiogenic agents.

Main Methods:

• Review of available clinical data.
• Analysis of studies on angiogenesis inhibitors and their surrogate markers.

Main Results:

• The development of clinically useful antiangiogenic therapy is complex.
• New methods and surrogate markers are essential for successful development.

Conclusions:

• Surrogate markers are crucial for assessing the efficacy and guiding the development of novel antiangiogenic agents.
• Further research into robust surrogate markers is needed to overcome the challenges in antiangiogenic therapy development.